Compare CubeSmart (CUBE) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CubeSmart vs Merck & Co., Inc. — how do they compare? CubeSmart trades at $40.86 (market cap $9.23B), while Merck & Co., Inc. trades at $130.41 (market cap $323.00B). The key difference: Merck & Co., Inc. is far larger — about 35× CubeSmart's market cap, and CubeSmart pays the higher dividend (5.17%). Which is the better fit depends on your goals.
| CUBE | MRK | |
|---|---|---|
Market Cap | $9.23B | $323.00B |
Sector | Real Estate | Health |
52-Week High | $42.50 | $131.84 |
52-Week Low | $35.36 | $77.60 |
Enterprise Value | $12.76B | $369.77B |
Dividend Yield | 5.17% | 2.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CubeSmart (CUBE) trades at $41.77, down slightly (-0.19%) on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $43.86 offering modest upside. The REIT has demonstrated consistent earnings beats in recent quarters and maintains strong profitability with a 29.41% net income margin. Recent news highlights improving operational trends, including higher occupancy and a raised full-year revenue outlook for 2026, suggesting a potential inflection point.
The outlook is cautiously optimistic, supported by operational momentum and a solid 5% dividend yield. Key risks include a high debt load, with long-term debt of $2.99 billion, and sensitivity to interest rate changes. While analyst sentiment is mixed (44.83% Buy, 51.72% Hold), the stock presents a value opportunity if operational improvements continue, though investors should weigh the debt burden against the stable income profile.
Merck (MRK) trades at $130.45, up 1.46% on the day, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported revenue of $65.01B in 2025 with a net income margin of 28.07%, though the P/E ratio of 104.74 reflects high valuation expectations. Recent acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, while dividend payments of $0.85 per share provide income stability.
Outlook remains positive with a consensus price target of $139.90, implying 7.2% upside, supported by 67.6% analyst buy ratings. Key risks include integration challenges from acquisitions, patent expirations, and regulatory pressures. Earnings growth and pipeline advancements are critical for sustaining the current premium valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CubeSmart
CubeSmart is a real estate investment trust that acquires, owns, and manages self-storage facilities throughout the United States. The company's real estate portfolio is composed of buildings with numerous enclosed storage areas for both residential and commercial customers to rent mainly on a month-by-month basis. Most of CubeSmart's facilities are located in Florida, Texas, California, New York, and Illinois. Cumulatively, these states account for both the majority of the square footage in the company's real estate portfolio and the majority of its revenue. CubeSmart derives nearly all of its revenue from rental income from tenants utilizing its storage facilities.
Read more on CUBE →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
